Lessons for Life Science Companies Developing or Marketing Medicines or Medical Devices
Pepper Hamilton partner Barry Boise recently spoke during Pepper’s Life Sciences Speaker Series and provided an overview of lessons learned from recent enforcement against companies that have run afoul of regulations in marketing pharmaceuticals.
In this podcast, Barry summarizes his key points from the event, including addressing the pitfalls companies may encounter when sharing data with investors, and the risks of engaging in off label interactions with health care professionals.
If you are interested in reading more about the latest legal developments in the life sciences industry, email firstname.lastname@example.org to subscribe to Pepper’s Life Sciences Updates.
(Running Time: 12:28)
Integration of IP and Regulatory Exclusivity Strategies for Emerging Life Science Companies
Raymond A. Miller and N. Nicole Endejann, Pittsburgh attorneys in Pepper Hamilton’s Intellectual Property Practice and Life Sciences Practice, and Tom Petzinger, Executive Vice President of Business Development and Public Affairs of Knopp Neurosciences Inc., identify the intellectual property and regulatory exclusivity strategies necessary for emerging life science companies to secure investments, strategic partnerships or licenses with third parties. In addition to reviewing critical IP strategies, this podcast discusses the recent Knopp – Biogen Idec transaction, in which Pepper served as IP counsel. Knopp developed the drug, dexpramipexole, for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, and potentially other indications. In August, Biogen Idec and Knopp Neurosciences entered into an exclusive, worldwide license agreement under which Biogen Idec will develop and commercialize the drug.
Email email@example.com to subscribe to Pepper Hamilton’s IP Alerts and Updates.
(Running Time: 26:28)